...
首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck
【24h】

Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck

机译:用多西他赛,顺铂和5-氟尿嘧啶诱导化疗,然后用西妥昔单抗放射治疗头颈部局部晚期鳞状细胞癌

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To determine the efficacy and feasibility of induction chemotherapy (ICT) with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy and cetuximab (C) in patients with locally advanced head and neck cancer. Patients and methods: Forty-nine previously untreated patients with local advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) received three courses of ICT consisting of docetaxel 75 mg/m 2 day 1, cisplatin 75 mg/m2 day 1 and infusional 5-fluorouracil 750 mg/m2/day on days 1-5 followed by radiotherapy plus C at 250 mg/m2/week (after an initial loading dose of 400 mg/m2). Results: After completion of ICT 44 of 49 patients received radiotherapy plus C. Three months after therapy completion tumour response was observed in 33 patients and after two years, 25 patients were in complete remission (CR). The most common grade 4 toxicity during the whole treatment period was dermatitis (30%), followed by mucositis (27%) and neutropenia (17%) without fever. One toxic related death was observed during ICT. Two-year progression-free survival (PFS) rate was 59% and two-year overall survival (OS) rate was 63%, respectively. Conclusion: Concurrent radiotherapy plus C after three courses of ICT was feasible and was associated with promising CR, PFS and OS rates. Further optimisation of dose and sequence is warranted.
机译:目的:确定多西他赛,顺铂和5-氟尿嘧啶诱导放化疗(ICT),放疗和西妥昔单抗(C)在局部晚期头颈癌患者中的疗效和可行性。患者和方法:49例先前未接受治疗的局部晚期III和IV期头颈部鳞状细胞癌(SCCHN)患者接受了三期ICT治疗,包括多西他赛75 mg / m 2天1,顺铂75 mg / m2天1和1-5天输注5-氟尿嘧啶750 mg / m2 /天,然后放疗加C剂量为250 mg / m2 /周(初始加载剂量为400 mg / m2后)。结果:完成ICT后,有49位患者接受放射疗法加C疗法。治疗结束后三个月,有33例患者观察到了肿瘤反应,两年后,有25例患者完全缓解(CR)。在整个治疗期间,最常见的4级毒性是皮炎(30%),其次是粘膜炎(27%)和中性粒细胞减少症(17%),无发热。在ICT期间观察到1例与毒性有关的死亡。两年无进展生存率(PFS)为59%,两年总生存率(OS)为63%。结论:ICT的三个疗程后同时放疗加C是可行的,并与有希望的CR,PFS和OS率相关。有必要进一步优化剂量和顺序。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号